21_REV-BIO-001-Logo-FINAL-RGB.jpg
Revolo Biotherapeutics Enters into Partnership Agreement with Northway Biotech to Manufacture its Novel Binding Immunoglobulin Protein, ‘1805, to Support Phase 2 Trials in Rheumatoid Arthritis and Uveitis
June 09, 2021 08:30 ET | Revolo Biotherapeutics
NEW ORLEANS and LONDON and WALTHAM, Mass. and VILNIUS, Lithuania, June 09, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that...
21_REV-BIO-001-Logo-FINAL-RGB.jpg
Revolo Biotherapeutics to Present at 3rd Annual Treg Directed Therapies Summit
May 14, 2021 08:00 ET | Revolo Biotherapeutics
NEW ORLEANS and LONDON, May 14, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
21_REV-BIO-001-Logo-FINAL-RGB.jpg
Revolo Biotherapeutics Announces Positive Data from Additional Phase 1 Clinical Trial of ‘1104, its Peptide Drug for Allergic Disease
May 04, 2021 08:30 ET | Revolo Biotherapeutics
NEW ORLEANS and LONDON, May 04, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
21_REV-BIO-001-Logo-FINAL-RGB.jpg
Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture ‘1104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease
April 15, 2021 08:00 ET | Revolo Biotherapeutics
NEW ORLEANS and LONDON, April 15, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior...
21_REV-BIO-001-Logo-FINAL-RGB.jpg
Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases
March 05, 2021 08:30 ET | Revolo Biotherapeutics
-- Plans to initiate four Phase 2 trials in second half of 2021-- -- Exploring additional autoimmune and allergic disease indications for portfolio candidates -- NEW ORLEANS and LONDON, March ...
nyibun4qrrrydmjdgf61.jpg
Immune Regulation to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
January 08, 2021 08:00 ET | Immune Regulation
LONDON AND NEW ORLEANS, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Immune Regulation, LTD, announced today that the company will give a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare...